The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Conversation with The Cancer Letter

Danny Milner: mRNA vaccines may become a viable treatment for cancer because of COVID-19 pandemic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The pandemic has accelerated the development of mRNA vaccines, which could have significant implications for cancer research, said Danny Milner, chief medical officer of the American Society for Clinical Pathology, and adjunct associate professor of immunology and infectious diseases in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health.

“If you say, this is an experimental vaccine we’ve never given to any other human ever, then you’re like, ‘Well, maybe I don’t want that, maybe I’ll want to try some other therapy,’ but if this is the same technology we gave to 3.5 billion people and saved millions of lives in COVID, it’s just a different protein than you have in your cancer, maybe the dialogue will be much better for the patient to accept it,” Milner said to The Cancer Letter.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account